BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18604173)

  • 21. Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
    Ahamed S; Foster JS; Bukovsky A; Diehl JA; Wimalasena J
    Mol Carcinog; 2002 May; 34(1):45-58. PubMed ID: 12112322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation.
    Leng X; Connell-Crowley L; Goodrich D; Harper JW
    Curr Biol; 1997 Sep; 7(9):709-12. PubMed ID: 9285720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The physiology of p16(INK4A)-mediated G1 proliferative arrest.
    Shapiro GI; Edwards CD; Rollins BJ
    Cell Biochem Biophys; 2000; 33(2):189-97. PubMed ID: 11325039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
    Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
    Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
    Whittaker SR; Walton MI; Garrett MD; Workman P
    Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
    Alcorta DA; Xiong Y; Phelps D; Hannon G; Beach D; Barrett JC
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13742-7. PubMed ID: 8943005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E2FBP1 antagonizes the p16(INK4A)-Rb tumor suppressor machinery for growth suppression and cellular senescence by regulating promyelocytic leukemia protein stability.
    Fukuyo Y; Takahashi A; Hara E; Horikoshi N; Pandita TK; Nakajima T
    Int J Oral Sci; 2011 Oct; 3(4):200-8. PubMed ID: 22010578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis.
    Semczuk A; Jakowicki JA
    Cancer Lett; 2004 Jan; 203(1):1-12. PubMed ID: 14670612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of hypoxia-induced apoptosis by modulation of retinoblastoma protein-dependent signaling in cardiomyocytes.
    Hauck L; Hansmann G; Dietz R; von Harsdorf R
    Circ Res; 2002 Nov; 91(9):782-9. PubMed ID: 12411392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor suppressor gene p16/INK4A/CDKN2A-dependent regulation into and out of the cell cycle in a spontaneous canine model of breast cancer.
    Agarwal P; Sandey M; DeInnocentes P; Bird RC
    J Cell Biochem; 2013 Jun; 114(6):1355-63. PubMed ID: 23238983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. E2F-1 but not E2F-4 can overcome p16-induced G1 cell-cycle arrest.
    Mann DJ; Jones NC
    Curr Biol; 1996 Apr; 6(4):474-83. PubMed ID: 8723352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression.
    Sugatani J; Osabe M; Kurosawa M; Kitamura N; Ikari A; Miwa M
    Drug Metab Dispos; 2010 Jan; 38(1):177-86. PubMed ID: 19797611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of p16 induces transcriptional downregulation of the RB gene.
    Fang X; Jin X; Xu HJ; Liu L; Peng HQ; Hogg D; Roth JA; Yu Y; Xu F; Bast RC; Mills GB
    Oncogene; 1998 Jan; 16(1):1-8. PubMed ID: 9467937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells.
    Fribourg AF; Knudsen KE; Strobeck MW; Lindhorst CM; Knudsen ES
    Cell Growth Differ; 2000 Jul; 11(7):361-72. PubMed ID: 10939590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Pezcoller lecture: cancer cell cycles revisited.
    Sherr CJ
    Cancer Res; 2000 Jul; 60(14):3689-95. PubMed ID: 10919634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.